The U.S. agreed to spend $2.1 billion on a joint experimental Covid-19 vaccine from GlaxoSmithKline and Sanofi to supply the nation with an initial 100 million doses by iamsternlicht
The U.S. agreed to spend $2.1 billion on a joint experimental Covid-19 vaccine from GlaxoSmithKline and Sanofi to supply the nation with an initial 100 million doses, bringing the country’s total vaccine spend under Operation Warp Speed to over $8 billion. Jakub Porzycki/NurPhoto via Getty ImagesMore than half of the $2.
Under the GSK-Sanofi deal, the U.S. will have the option to purchase up to 500 million additional doses . “The global need for a vaccine to help prevent COVID-19 is massive, and no single vaccine or company will be able to meet the global demand alone,” said Executive Vice President and Global Head of Sanofi Pasteur Thomas Triomphe in the July 31In addition to clinical trials, the money will also be used on manufacturing and delivery of the initial 100 million doses.
The companies are working with other nations to manufacture 1 billion doses of the vaccine annually for use across the globe.That’s how much the U.S.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Are Face Shields Better Than Face Masks For Protection Against COVID-19?Experts debate how effective face shields are in reducing the spread of the coronavirus.
Read more »
Roche Arthritis Drug Fails Covid-19 TestingArthritis drug Actemra was no better than a placebo in improving Covid-19 patients’ clinical status, including the need for ventilators or intensive care
Read more »
U.S. economy likely suffered historic plunge in second quarter; outlook murky as COVID-19 cases surgeThe U.S. economy likely contracted at its steepest pace since the Great Depression in the second quarter as the COVID-19 pandemic destroyed consumer and business spending, potentially wiping out more than five years of growth.
Read more »